Publicaciones en colaboración con investigadores/as de Complejo Asistencial de Segovia (11)

2022

  1. Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain)

    BMC Geriatrics, Vol. 22, Núm. 1

  2. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

2021

  1. Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized With COVID-19 in Spain

    The journals of gerontology. Series A, Biological sciences and medical sciences, Vol. 76, Núm. 3, pp. e28-e37

  2. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  3. Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients

    Scientific Reports, Vol. 11, Núm. 1

  4. Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry

    PLoS ONE, Vol. 16, Núm. 2 February

  5. The prognostic value of eosinophil recovery in COVID-19: A multicentre, retrospective cohort study on patients hospitalised in spanish hospitals

    Journal of Clinical Medicine, Vol. 10, Núm. 2, pp. 1-23

2020

  1. Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2

    International journal of chronic obstructive pulmonary disease, Vol. 15, pp. 3433-3445

2017

  1. Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme

    PLoS ONE, Vol. 12, Núm. 3

  2. Response to bile salts in clinical strains of Acinetobacter baumannii lacking the adeABC efflux pump: Virulence associated with quorum sensing

    Frontiers in Cellular and Infection Microbiology, Vol. 7, Núm. MAY

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092